Hepatic sinusoidal obstruction syndrome (SOS) remains a serious complication of hematopoietic stem cell transplantation (HSCT). In this single institution retrospective case series, 18 children developed SOS after HSCT. Patients were treated with antithrombin III (ATIII), defibrotide, or ATIII followed by defibrotide. Twelve of 13 patients who were treated with ATIII therapy alone had complete resolution of SOS, including 4 of 5 children with severe SOS. In this limited cohort, ATIII was safe and successfully prevented progression of hepatic SOS following HSCT in the majority of children at our center.
Bibliographical noteFunding Information:
M.K. is supported by a St. Baldrick’s Foundation Fellowship award. S.R. was supported by an National Institutes of Health (NIH) grant T32 CA009614. C.M.C. is supported by the NIH/National Cancer Insti-tute grant K08 CA174750. None of these funding sources had any input in the study design, analysis, manuscript preparation, or deci-sion to submit for publication.
© 2019 Wolters Kluwer Health, Inc. All rights reserved.
- antithrombin III
- sinusoidal obstruction syndrome
- stem cell transplantation
- venoocclusive disease
PubMed: MeSH publication types
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't